RxDoctor Payments Data

Neha Pansuria, MD

Rheumatology · Bowling Green, KYNPI 1659534071

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (49.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Boehringer Ingelheim at 39.4% of the total. Among rheumatology clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$39,129in general payments, 2019–2025

Across 1,107 payments — averaging $35.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$15K
  • Amgen$4K
  • Johnson & Johnson$4K
  • AbbVie$4K
  • Fresenius Kabi USA, LLC$2K
  • UCB, Inc.$2K
  • plus $9K from 35 others

What the payments were for

  • Consulting fees$16,03341%
  • Speaking & faculty fees$4001%
  • Travel & lodging$2,9297%
  • Food & beverage$19,48550%
  • Education$2831%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$39,129 in reported general payments places this provider in the 90th percentile of 81 rheumatology providers in Kentucky.

See all rheumatology providers in Kentucky

Medicare billing

Part B allowed, 2024
$1,257,738
Medicare patients
450
Services billed
71,254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept164$1,193,199
Humira(Cf) PenAdalimumab75$573,403
Humira PenAdalimumab42$295,243
RinvoqUpadacitinib43$276,477
OtezlaApremilast24$113,258
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5014$107,383
Cyltezo(Cf) PenAdalimumab-Adbm13$90,418
EnbrelEtanercept11$81,548
XeljanzTofacitinib Citrate14$79,410
BenlystaBelimumab16$76,876
OrenciaAbatacept11$58,553
ProliaDenosumab13$23,042
MethotrexateMethotrexate Sodium833$7,431
Celecoxib218$6,021
Hydroxychloroquine Sulfate519$5,330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Savella$3,724$280,77057 claims
AmgenOtezla, Enbrel, Prolia$3,938$217,84848 claims
PfizerXeljanz$704$79,41014 claims
GSKBenlysta$942$76,87616 claims
E.r. Squibb & Sons, L.L.C.Orencia$522$58,55311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 81 rheumatology providers in Kentucky.

Other rheumatology in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →